JP2020518627A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518627A5
JP2020518627A5 JP2019560299A JP2019560299A JP2020518627A5 JP 2020518627 A5 JP2020518627 A5 JP 2020518627A5 JP 2019560299 A JP2019560299 A JP 2019560299A JP 2019560299 A JP2019560299 A JP 2019560299A JP 2020518627 A5 JP2020518627 A5 JP 2020518627A5
Authority
JP
Japan
Prior art keywords
alkyl
group
pharmaceutically acceptable
hydrate
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019560299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518627A (ja
JP7295034B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030909 external-priority patent/WO2018204661A1/en
Publication of JP2020518627A publication Critical patent/JP2020518627A/ja
Publication of JP2020518627A5 publication Critical patent/JP2020518627A5/ja
Application granted granted Critical
Publication of JP7295034B2 publication Critical patent/JP7295034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019560299A 2017-05-05 2018-05-03 癌関連障害の治療のためのキナゾリン-ピリジン誘導体 Active JP7295034B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762502391P 2017-05-05 2017-05-05
US62/502,391 2017-05-05
US201862624273P 2018-01-31 2018-01-31
US62/624,273 2018-01-31
PCT/US2018/030909 WO2018204661A1 (en) 2017-05-05 2018-05-03 Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Publications (3)

Publication Number Publication Date
JP2020518627A JP2020518627A (ja) 2020-06-25
JP2020518627A5 true JP2020518627A5 (cg-RX-API-DMAC10.html) 2022-08-12
JP7295034B2 JP7295034B2 (ja) 2023-06-20

Family

ID=64016681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019560299A Active JP7295034B2 (ja) 2017-05-05 2018-05-03 癌関連障害の治療のためのキナゾリン-ピリジン誘導体

Country Status (9)

Country Link
US (1) US11045472B2 (cg-RX-API-DMAC10.html)
EP (1) EP3618829B1 (cg-RX-API-DMAC10.html)
JP (1) JP7295034B2 (cg-RX-API-DMAC10.html)
CN (1) CN110612100B (cg-RX-API-DMAC10.html)
ES (1) ES2953349T3 (cg-RX-API-DMAC10.html)
PL (1) PL3618829T3 (cg-RX-API-DMAC10.html)
TW (1) TWI789393B (cg-RX-API-DMAC10.html)
UY (1) UY37725A (cg-RX-API-DMAC10.html)
WO (1) WO2018204661A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110636846B (zh) * 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
CN109293586A (zh) * 2018-11-22 2019-02-01 云南师范大学 一种在氨水中微波条件下卤代苯甲酸合成喹唑啉酮化合物的方法
WO2020146563A1 (en) * 2019-01-10 2020-07-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers such as spp to increase tumor immunity and improve the efficacy of cancer immunotherapy
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
AU2021213969A1 (en) * 2020-01-30 2022-09-01 ONA Therapeutics S.L. Combination therapy for treatment of cancer and cancer metastasis
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
CA3179320A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
KR20230158044A (ko) 2021-03-18 2023-11-17 남미 테라퓨틱스, 인크. 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
EP4341262A1 (en) 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl inhibitor compounds
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
TW202325279A (zh) 2021-10-29 2023-07-01 美商阿克思生物科學有限公司 HIF-2α抑制劑及其使用方法
CN119156228A (zh) 2022-05-02 2024-12-17 艾库斯生物科学有限公司 抗tigit抗体及其用途
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
EP4705292A1 (en) 2023-05-05 2026-03-11 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN119462487A (zh) * 2023-08-08 2025-02-18 重庆博腾制药科技股份有限公司 一种阿培利司中间体4-甲基吡啶类化合物的制备方法
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
EP4788432A1 (en) 2023-10-06 2026-08-12 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same
WO2026035034A1 (ko) * 2024-08-06 2026-02-12 주식회사 대웅제약 신규한 퀴나졸린 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1397364T1 (sl) 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
TWI330183B (cg-RX-API-DMAC10.html) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
WO2004106337A1 (en) 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
CA2551944A1 (en) 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
TW200813056A (en) * 2006-06-29 2008-03-16 King Pharmaceuticals Res Dev Inc Adenosine A2B receptor antagonists
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
WO2010033906A2 (en) * 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
US8871744B2 (en) * 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2016126570A1 (en) 2015-02-06 2016-08-11 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist

Similar Documents

Publication Publication Date Title
JP2020519664A5 (cg-RX-API-DMAC10.html)
JP2020111618A5 (cg-RX-API-DMAC10.html)
JP2021531314A5 (cg-RX-API-DMAC10.html)
Alsaif et al. Discovery of new VEGFR-2 inhibitors based on bis ([1, 2, 4] triazolo)[4, 3-a: 3', 4'-c] quinoxaline derivatives as anticancer agents and apoptosis inducers
JP2019529500A5 (cg-RX-API-DMAC10.html)
JP2019535720A5 (cg-RX-API-DMAC10.html)
TWI690525B (zh) 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
JP2022507474A5 (cg-RX-API-DMAC10.html)
ES2908938T3 (es) Nuevos derivados de benzamida como moduladores de PPAR-gamma
JP2017538677A5 (cg-RX-API-DMAC10.html)
JP2022524559A5 (cg-RX-API-DMAC10.html)
JP2019501223A5 (cg-RX-API-DMAC10.html)
JP2018532690A5 (cg-RX-API-DMAC10.html)
CN105683201B (zh) 新的含n‑杂环碳烯配体的金(iii)络合物、合成及其在癌症治疗和硫醇检测中的应用
CN110573500A (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
JP2010526096A5 (ja) キナーゼ阻害剤として有用なチアゾールおよびピラゾール
JP2016538344A5 (cg-RX-API-DMAC10.html)
KR20190041471A (ko) 케모카인 수용체 조절제 및 이의 용도
JP2017514855A5 (cg-RX-API-DMAC10.html)
CN110896634A (zh) 作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物
JP2016503414A5 (cg-RX-API-DMAC10.html)
JP2015536997A5 (cg-RX-API-DMAC10.html)
JP2013544846A5 (cg-RX-API-DMAC10.html)
Aruchamy et al. Design, synthesis, and anti-breast cancer potential of imidazole–pyridine hybrid molecules in vitro and ehrlich ascites carcinoma growth inhibitory activity assessment in vivo
JP2020527173A5 (cg-RX-API-DMAC10.html)